October 2018 Briefing – Ophthalmology

Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for October 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

AMA Announces Initiative to Reinvent Physician Training

TUESDAY, Oct. 30, 2018 (HealthDay News) — The American Medical Association (AMA) today announced a new $15 million competitive grant initiative, the “Reimagining Residency” initiative, aimed at improving residency training.

More Information

Many Hospitals Noncompliant With Record Request Regulations

MONDAY, Oct. 29, 2018 (HealthDay News) — Among top-ranked U.S. hospitals, data reveal discrepancies in information provided to patients regarding medical records release processes as well as noncompliance with state and federal regulations, according to a study published online Oct. 5 in JAMA Network Open.

Abstract/Full Text

Trump Administration Announces Plan to Cut Drug Prices

FRIDAY, Oct. 26, 2018 (HealthDay News) — In an effort to cut high drug costs, the prices paid by Medicare for certain prescription drugs would be based on those in other advanced industrial nations, according to a proposal announced Oct. 25 by the Trump administration.

HHS Study
New York Times Article

Pace of Change Has Accelerated in Alternative Payment Models

THURSDAY, Oct. 25, 2018 (HealthDay News) — The impact of alternative payment models (APMs) on physician practices has been described in a study published by the RAND Corp. and the American Medical Association.

More Information

Most Supplements Contain Prohibited Stimulants

WEDNESDAY, Oct. 24, 2018 (HealthDay News) — Many supplements contain one or more stimulants that have been the subject of U.S. Food and Drug Administration-issued public notices, according to a research letter published online Oct. 22 in JAMA Internal Medicine.

Abstract/Full Text (subscription or payment may be required)
Editor’s Note (subscription or payment may be required)

Myo-Inositol Does Not Reduce Retinopathy of Prematurity

WEDNESDAY, Oct. 24, 2018 (HealthDay News) — Treatment with myo-inositol for up to 10 weeks does not reduce the risk for type 1 retinopathy of prematurity (ROP) or death versus placebo for premature infants younger than 28 weeks of gestational age, according to a study published in the Oct. 23/30 issue of the Journal of the American Medical Association.

Abstract/Full Text (subscription or payment may be required)

White House Unveils New Insurance Option for Small Firms

TUESDAY, Oct. 23, 2018 (HealthDay News) — A plan to allow small businesses to use tax-free accounts to provide health coverage for employees was announced today by the Trump administration.

AP News Article
More Information

Procurement Requirements Drive Interoperability in Health Care IT